99%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

YN968D1

Powder

DMSO：22 mg/mL (44.57 mM)

VEGFR2 ,RET

Apatini (YN968D1) is a novel, orally bioavailable, selective inhibitor with potential antiangiogenic and antineoplastic activities. Apatini selectively binds to and inhibits VEGFR2. Apatini can also potently suppress the activities of Ret, c-kit and c-src with IC50 of 0.013 μM, 0.429 μM and 0.53 μM, respectively. Apatini inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ. Apatini significantly inhibits proliferation stimulated by 20 ng/mL VEGF (IC50 = 0.17μM). Apatini effectively inhibits proliferation, migration and tube formation of human umbilical vein endothelial cells induced by FBS, and blocked the budding of rat aortic ring. Apatini reverses ABCB1- and ABCG2-mediated MDR by inhibiting their transport function, but not by blocking the AKT or ERK1/2 pathway or downregulating ABCB1 or ABCG2 expression. Apatini significantly potentiates the cytotoxicity of established ABCB1 and ABCG2 substrates and increased the accumulation of DOX and Rho 123 in ABCB1- or ABCG2-overexpressing cells. Furthermore, apatini significantly inhibited the photoaffinity labeling of both ABCB1 and ABCG2 with iodoarylazidoprazosin in a concentration-dependent manner.

Apatini inhibits the growth of a broad range of human tumor xenografts in a significant dose-dependent manner. Apatini reverses ABCB1-mediated MDR in the nude mouse xenograft model. Apatini significantly enhances the antitumor activity of doxorubicin in nude mice bearing K562/ADR xenografts.

1] Tian S, et al. Cancer Sci, 2011, 102(7), 1374-1380.
[2] Mi YJ, et al. Cancer Res, 2010, 70(20), 7981-7991.
[3] Tong XZ, et al. Biochem Pharmacol, 2012, 83(5), 586-597.